



# BETA DRUGS LIMITED

BDL/PKL/SEC/2023

7<sup>th</sup> November, 2023

National Stock Exchange of India Ltd.  
Exchange Plaza, 5th Floor  
Plot no. C/I, G Block  
Bandra-Kurla Complex, Bandra (E)  
Mumbai — 400 051.

## SYMBOL-BETA

**Sub:** Outcome of Board Meeting of Beta Drugs Limited-7<sup>th</sup> November, 2023

With reference to above captioned subject matter we would like to inform you that Board of Directors of Beta Drugs Limited in their meeting held today i.e. 7<sup>th</sup> November, 2023, at 10:00 AM at the Corporate Office of the company situated at SCO-184, Sector-5, Panchkula-134114 has considered and approved the following agenda items:-

1. the un-audited Standalone & Consolidated financial results alongwith limited review report under regulation 33 of SEBI (LODR) Regulation, 2015 for the half year ended 30<sup>th</sup> September, 2023.
2. Considered and approved the proposal of Migration of Equity Shares of the Company from NSE SME Platform to the Main Board of National Stock Exchange of India Limited ("NSE") & Bombay Stock Exchange of India Limited (BSE) subject to the approval of Members of the Company.

Pursuant to Regulation 33 of SEBI (Listing Obligation & Disclosure Requirements) Regulation, 2015, we are enclosing herewith the following documents:

1. Management Discussion & Analysis.
2. Limited review Report on Consolidated Financial Results alongwith Un-Audited Consolidated Financial Results for the half year ended 30<sup>th</sup> September, 2023.
3. Limited review Report on Standalone Financial Results alongwith Un-Audited Standalone Financial Results for the half year ended 30<sup>th</sup> September, 2023.
4. Certificate as per regulation 33(2)(a) of SEBI (LODR) Regulations, 2015

The meeting of the Board of Directors commenced at 10.00 a.m. and concluded at 4:15 p.m.

This is for your information and appropriate dissemination.

Thanking You

Your's faithfully  
For Beta Drugs Ltd.

Rajni Brar

CIN No.: L24230HP2005PLC028969

Company Secretary, SCO 184, Sector-5, Panchkula-134 114 Haryana (INDIA) Phone: +91-172-2585481-482-483

**Registered Office & Works:** Vill. Nandpur, Lodhimajra Road, Tehsil. : Baddi, Distt. Solan, H.P. Phone No. : 01795-236196

**Website :-** www.betadrugslimited.com

**E-Mail :-** info@betadrugslimited.com



# BETA DRUGS LIMITED

## MANAGEMENT DISCUSSION & ANALYSIS

Beta consolidated revenues from operations for the first six months of FY24 increased by 26% to Rs. 141.3 crores from Rs 112.4 crores compared with the same period a year ago due to growth across all its segments.

Consolidated EBITDA came at Rs. 33.4 crores while EBITDA margins stood at 23.64%. However, considering the impact of Derma business the consolidated EBITDA was Rs 33.6 crores.

Net profit too increased by 26% to Rs 19.9 crores from Rs 15.8 crores compared with the same period a year ago. Net profit margin came at 14.07%.

Beta continues to be net debt free. Cash & Cash Equivalents are in surplus by Rs. 8 crores over the borrowings. Furthermore, after this Balance Sheet we received the subsidy funds from Himachal Government in October, 2023 and we repaid the borrowings to the tune of Rs. 4 crores.

Beta continues to be among the fastest growing scaled up companies in Indian branded oncology pharma market. The company's focus on novel delivery and formulation development innovation has helped to establish differentiation in the Indian market.


After having received ANVISA and INVIMA approvals recently, the company is well positioned for growth in semi-regulated and emerging markets

Beta's vertically integrated operations with built in cost efficiencies has helped the continuous expansion of margins over the years.

## **GUIDANCE FOR SECOND HALF**

Beta is perched on the threshold of accelerating growth and expanding margins. Management expects to better its first half's financial performance. It expects revenues for FY24 at Rs 290+ crores aided by strong momentum across all its four segments; Own Brands, Exports, OEMs & API. EBITDA margins are expected to improve further aided by Beta's strong R&D engine with differentiated offerings including NDDS and FTL/ FCTL pipeline which will help drive strong growth over many years to come. Beta was among the first few companies to launch Nilotinib in September 2023 and is on track to commercialize two NDDS products in Dec 2023 which will cement its position as a leading player in Indian oncology market.

The Company continues to invest aggressively in R&D, talent and product dossiers which are expected to accelerate growth going forward.



**CIN No.:** L24230HP2005PLC028969

**Admin. Office :** SCO 184, Sector-5, Panchkula-134 114 Haryana (INDIA) Phone: +91-172-2585481-482-483

**Registered Office & Works:** Vill. Nandpur, Lodhimajra Road, Tehsil. : Baddi, Distt. Solan, H.P. Phone No. : 01795-236196

**Website :-** [www.betadrugslimited.com](http://www.betadrugslimited.com)

**E-Mail :-** [info@betadrugslimited.com](mailto:info@betadrugslimited.com)





**KALRA RAI & ASSOCIATES**  
**A Peer Review Firm**  
**CHARTERED ACCOUNTANTS**

M : +91-98880-66743

Phone - 0172-4640667

E-mail : kalrarai@gmail.com

kalrarai667@hotmail.com

Head Office : Kothi No. 667, 1st Floor, Sector-43 A, Chandigarh - 160022

**LIMITED REVIEW REPORT**

**Independent Auditor's Review report on Interim Un-Audited Consolidated Financial Results for the half year ended on 30<sup>th</sup> September, 2023 pursuant to Regulation 33 of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015 ( as amended)**

To,  
The Board of Directors of  
M/s Beta Drugs Limited  
Village Nandpur, Lodhimajra Road  
Baddi, Distt Solan  
H.P. 174101

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of M/S BETA DRUGS LIMITED ("the Parent") and its subsidiary ("the Parent" and its subsidiaries together referred to as "the Group"), and its share of the net profit/(loss) after tax for the half year ended 30th September, 2023, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Attention is drawn to the fact that the consolidated figures for the corresponding half ended 30/09/2023 as reported in these financial results have been approved by the Parent's Board of Directors, and have been subjected to review.

2. This Statement is the responsibility of the Parent's Management and has been approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

**Branch Office Mohali :-**


Plot No. 775, Sector-82, JLPL, Mohali, Punjab-160082

EMAIL : kalrarai@rediffmail.com

**Branch Office Delhi :-**

I-50, 4th Floor, Lagpat Nagar-1, New Delhi - 110024, Ph. : 011-43034803

EMAIL : advphagunkalra@gmail.com | Cell : +91-77989-06173







**KALRA RAI & ASSOCIATES**  
**A Peer Review Firm**  
**CHARTERED ACCOUNTANTS**

M : +91-98880-66743

Phone - 0172-4640667

E-mail : kalrarai@gmail.com

kalrarai667@hotmail.com

Head Office : Kothi No. 667, 1st Floor, Sector-43 A, Chandigarh - 160022

4. The Statement includes the results of the following entities:

Name of the Company	Relation
Adley Formulations Pvt Ltd	Indian Subsidiary (wholly owned)
Adley Lab Limited	Indian Subsidiary (wholly owned)
Beta Research Private Limited	Indian Subsidiary (wholly owned)

5. Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited consolidated financial results, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. Our conclusion is not modified in respect of this matter.

7. The consolidated unaudited financial results includes the interim unaudited financial statements/ financial information/financial results of Adley Formulations Pvt Ltd (its subsidiary), Adley Lab Limited (its subsidiary)& Beta Research Private Limited(its subsidiary)which have not been reviewed/audited by their auditors, whose interim financial statements/ financial information/ financial results reflect total assets of Rs. 82,15,92,530.83/- as at 30th September, 2023and total revenue of Rs.48,73,06,129.23/-, total net profit/(loss) after tax of Rs.7,76,15,963.25/- and total comprehensive income / loss of Rs. Nil,for the half year ended 30th September, 2023 , respectively, and cash flows (net)of Rs. 19,56,360.26/- for the period from 1st April,2023 to 30th September, 2023, as considered in the consolidated unaudited financial results whose financial statement are not audited by us.This financial statement whose report have been furnished to us by the management and our opinion on the consolidated financial results in so far as it related to the amount and disclosure included in respect of this subsidiary is based solely on the reports of the management and procedure performed by us as stated in paragraph above.

For KALRA RAI & ASSOCIATES  
Chartered Accountants

(LAJPAT RAI KALRA)

Partner

M. No.:-087438

Place: Chandigarh

Date: 07.11.2023

**Branch Office Mohali :-**

Plot No. 775, Sector-82, JLPL, Mohali, Punjab-160082

EMAIL : kalrarai@rediffmail.com

**Branch Office Delhi :-**

I-50, 4th Floor, Lagpat Nagar-1, New Delhi - 110024, Ph. : 011-43034803

EMAIL : advphagunkalra@gmail.com | Cell : +91-77989-06173



**BETA DRUGS LIMITED**

Village Nandpur, Lodhimajra Road, Tehsil. Baddi, Distt. Solan, (H.P.) 173205

Phone : 01795-236196 E-Mail : betabaddi@gmail.com

CIN No. L24230HP2005PLC028969

Audited Consolidated Financial Results for the year ended on 30th September' 2023

Particulars	6 Months Ended on 30/09/2023 (Unaudited)	6 Months Ended on 31/03/2023 (Audited)	6 Months Ended on 30/09/2022 (Unaudited)	Year Ended on 31/03/2023 (Audited)
I. Revenue From Operations	1,41,26,86,006.43	1,14,72,31,009.38	1,12,39,04,984.87	2,27,11,35,994.25
II. Other Income	53,65,793.02	42,72,693.76	32,62,461.54	75,35,155.30
<b>III. Total Revenue (I+II)</b>	<b>1,41,80,51,799.45</b>	<b>1,15,15,03,703.14</b>	<b>1,12,71,67,446.41</b>	<b>2,27,86,71,149.55</b>
<b>IV. Expenses</b>				
a) Cost of Materials Consumed	79,70,72,269.86	57,10,10,441.89	53,30,11,548.35	1,10,40,21,990.24
b) Purchase of Stock-in-Trade	-	-	-	-
c) (Increase)/Decrease in Stock of Finished Goods/WIP	(10,66,96,178.76)	(4,92,39,517.17)	21,11,444.02	(4,71,28,073.15)
d) Other Manufacturing expenses	15,09,52,450.95	11,98,35,607.95	11,68,31,300.02	23,81,60,642.23
e) Employee benefit expenses	12,10,53,595.12	11,76,03,800.41	10,93,64,675.96	22,69,68,476.37
f) Finance Costs	1,37,05,153.47	1,27,41,974.27	1,14,05,849.82	2,41,47,824.09
g) Depreciation & amortisation expenses	5,43,97,189.20	5,57,60,132.57	4,83,40,141.46	10,41,00,274.02
h) Other expenses	12,17,40,832.10	12,48,27,810.42	9,45,00,550.29	21,78,34,626.45
<b>Total Expenses</b>	<b>1,15,22,25,311.94</b>	<b>95,25,40,250.34</b>	<b>91,55,65,509.92</b>	<b>1,86,81,05,760.25</b>
<b>V. Profit before exceptional and extraordinary items and tax (III-IV)</b>	<b>26,58,26,487.51</b>	<b>19,89,63,452.80</b>	<b>21,16,01,936.49</b>	<b>41,05,65,389.30</b>
<b>VI. Exceptional Items</b>	-	-	-	-
<b>VII. Profit before extraordinary items and tax (V-VI)</b>	<b>26,58,26,487.51</b>	<b>19,89,63,452.80</b>	<b>21,16,01,936.49</b>	<b>41,05,65,389.30</b>
<b>VIII. Extraordinary Items</b>	-	-	-	-
<b>IX. Profit before tax (VII-VIII)</b>	<b>26,58,26,487.51</b>	<b>19,89,63,452.80</b>	<b>21,16,01,936.49</b>	<b>41,05,65,389.30</b>
<b>X. Tax Expenses</b>				
a) Current year tax	6,91,59,454.25	5,33,47,610.72	5,52,37,777.27	10,85,85,388.00
b) MAT credit/Deferred tax	(20,64,325.11)	(32,25,371.23)	(19,81,800.94)	(52,07,172.17)
<b>XI. Profit (Loss) for the period from continuing operations (IX-X)</b>	<b>19,87,31,358.37</b>	<b>14,88,41,213.31</b>	<b>15,83,45,960.16</b>	<b>30,71,87,173.47</b>
<b>XII. Profit (Loss) from discounting operations</b>				
<b>XIII. Tax expenses of discounting operations</b>				
<b>XIV. Profit (Loss) from discounting operation (after tax) (XII-XIII)</b>	-	-	-	-
<b>XV. Net Profit/(Loss) for the period (XI+XIV)</b>	<b>19,87,31,358.37</b>	<b>14,88,41,213.31</b>	<b>15,83,45,960.16</b>	<b>30,71,87,173.47</b>
<b>XVI. Earning per share</b>				
a) Basic	20.67	15.48	16.47	31.95
b) Diluted	20.67	15.48	16.47	31.95
<b>XVIII. Paid up equity share capital</b>	<b>9,61,37,900.00</b>	<b>9,61,37,900.00</b>	<b>9,61,37,900.00</b>	<b>9,61,37,900.00</b>
<b>Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year</b>	<b>1,32,36,45,519.92</b>	<b>1,13,27,04,067.17</b>	<b>98,41,17,417.43</b>	<b>1,13,27,04,067.17</b>

1 The above results have been reviewed by the Audit Committee and taken on record by Board of Directors at their respective meetings held at 07th November' 2023.

2 The company is engaged in single business segment i.e. Pharmaceuticals.

3 Figures are regrouped/rearranged, wherever considered necessary.

For KALRA RAI AND ASSOCIATES

Chartered Accountants

(FRN : 008859N)

Chartered  
Accountants  
FRN-008859N


LALPAT RAI KALRA  
PARTNER

Membership No. : 087438

UDIN: 23087438BQVHLR7940

Place : Chandigarh

Date : 07/11/2023



RAHUL BATRA  
MANAGING DIRECTOR  
DIN : 02229234

For and on Behalf of Board of Directors



RAJNI BRAR  
COMPANY SECRETARY  
ACS24684



NIPUN ARORA  
CFO  
FCA514044



# BETA DRUGS LIMITED

Village Nandpur, Lodhimajra Road, Tehsil. Baddi, Distt. Solan, (H.P.) 173205

Phone : 01795-236196 E-Mail : betabaddi@gmail.com

CIN No. L24230HP2005PLC028969

## Consolidated Statement of Assets & Liabilities for the year ended on 30th September' 2023

Particulars	As at 30th September' 2023 Amount in Rs.	As at 31st March' 2023 Amount in Rs.	As at 30th September' 2022 Amount in Rs.
<b>1. EQUITY AND LIABILITIES</b>			
<b>(A) Shareholder's Funds</b>			
(a) Share Capital	9,61,37,900.00	9,61,37,900.00	9,61,37,900.00
(b) Reserves and Surplus	1,32,36,45,519.92	1,13,27,04,067.17	98,41,17,417.43
(c) Money received against share warrants	-	-	-
<b>Sub-total-Shareholders' funds</b>	<b>1,41,97,83,419.92</b>	<b>1,22,88,41,967.17</b>	<b>1,08,02,55,317.43</b>
<b>(B) Non- Current Liabilities</b>			
(a) Long-term borrowings	6,05,79,876.06	6,97,38,034.01	6,68,54,967.00
(b) Deferred tax liabilities (Net)	-	-	-
(c) Other Long term liabilities	4,13,64,641.94	3,71,88,588.62	3,94,38,232.30
(d) Long term Provisions	1,81,36,049.00	1,82,87,036.00	1,43,19,603.00
<b>Sub-total-Non- current liabilities</b>	<b>12,00,80,567.00</b>	<b>12,52,13,658.63</b>	<b>12,06,12,802.30</b>
<b>(C) Current Liabilities</b>			
(a) Short-term borrowings	9,36,58,099.07	9,06,85,133.11	8,93,19,726.81
(b) Trade Payable	55,99,08,266.58	40,24,03,648.57	31,83,74,650.71
(c) Other current liabilities	13,69,53,427.16	9,53,69,362.80	9,81,02,925.63
(d) Short-term provisions	4,22,85,611.07	4,17,00,950.37	4,55,86,391.99
<b>Sub-total-current liabilities</b>	<b>83,28,05,403.88</b>	<b>63,01,59,094.85</b>	<b>55,13,83,695.14</b>
<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>2,37,26,69,390.80</b>	<b>1,98,42,14,720.65</b>	<b>1,75,22,51,814.88</b>
<b>2. ASSETS</b>			
<b>(A) Non-current assets</b>			
(a) Property, Plant & Equipment and Intangible Assets			
(i) Property, Plant & Equipment	59,16,82,701.40	58,09,46,351.08	54,70,87,846.42
(ii) Intangible assets	5,11,56,308.26	4,66,22,694.40	4,22,87,948.79
(iii) Capital work-in-progress	-	-	-
(b) Non Current Investments	-	77,89,905.49	77,89,905.49
(c) Long Term Loan & Advance	7,57,00,124.44	5,95,02,750.97	4,59,16,056.58
(d) Other Non Current Assets	5,00,000.00	5,00,000.00	5,00,000.00
(e) Deferred tax Assets	1,40,70,821.14	1,20,06,496.08	87,81,124.95
<b>Sub-total-Non-current assets</b>	<b>73,31,09,955.24</b>	<b>70,73,68,198.02</b>	<b>65,23,62,882.24</b>
<b>(B) Current Assets</b>			
(a) Inventories	45,11,81,992.46	30,61,87,023.02	21,85,18,830.28
(b) Trade receivable	77,70,65,596.12	62,72,26,745.59	60,07,53,325.44
(c) Cash and bank balance	23,35,43,211.52	19,16,39,636.83	16,04,08,996.59
(d) Short-term loan and advances	7,31,05,389.12	6,09,02,324.96	4,48,45,085.88
(e) Other current assets	10,46,63,246.34	9,08,90,792.23	7,53,62,694.45
<b>Sub-total-current assets</b>	<b>1,63,95,59,435.56</b>	<b>1,27,68,46,522.63</b>	<b>1,09,98,88,932.64</b>
<b>TOTAL - ASSETS</b>	<b>2,37,26,69,390.80</b>	<b>1,98,42,14,720.65</b>	<b>1,75,22,51,814.88</b>

- The above results have been reviewed by the Audit Committee and taken on record by Board of Directors at their respective meetings held at 07th November' 2023.
- The company is engaged in single business segment i.e. Pharmaceuticals.
- Figures are regrouped/rearranged, wherever considered necessary.

For KALRA RAI AND ASSOCIATES

Chartered Accountants

(FRN : 008859N)

Accountants  
FRN 008859N

LAJPAT RAI KALRA  
PARTNER

Membership No. : 087438

UDIN: 23087438BQVHLR7940

Place : Chandigarh

Date : 07/11/2023

RAHUL BATRA  
MANAGING DIRECTOR  
DIN : 02229234

RAJNI BRAR  
COMPANY SECRETARY  
ACS24684

NIPUN ARORA  
CFO  
FCA514044

For and on Behalf of Board of Directors



**BETA DRUGS LIMITED**

Village Nandpur, Lodhimajra Road, Tehsil. Baddi, Distt. Solan, (H.P.) 173205

Phone : 01795-236196 E-Mail : betabaddi@gmail.com

CIN No. L24230HP2005PLC028969

**Consolidated Cashflow Statement for the year ended on 30th September' 2023**

Particulars	As at 30 September' 2023	As at 31 March' 2023	As at 30 September' 2022
	Amount in Rs.	Amount in Rs.	Amount in Rs.
<b>A CASHFLOW FROM OPERATING ACTIVITIES</b>			
Net Profit before tax and extraordinary items (as per Statement of Profit & Loss)	26,58,26,487.51	41,05,65,389.30	21,16,01,936.49
Adjustments for non Cash/Non trade items:			
Depreciation & Amortization Expenses	5,43,97,189.20	10,41,00,274.02	4,83,40,141.46
Finance Cost	1,37,05,153.47	2,41,47,824.09	1,14,05,849.82
Interest received	(45,31,698.19)	(66,29,830.03)	(29,51,597.54)
Other inflows/(outflows) of cash	(7,65,15,686.04)	(10,14,22,944.48)	(4,79,02,761.66)
<b>Operating profits before Working Capital Changes</b>	<b>25,28,81,445.95</b>	<b>43,07,60,712.90</b>	<b>22,04,93,568.57</b>
<b>Adjusted For:</b>			
(Increase)/Decrease in trade receivables	(14,98,38,850.53)	(17,54,08,135.12)	(14,89,34,714.97)
Increase/(Decrease) in trade payables	15,75,04,618.01	8,28,84,185.25	(11,44,812.61)
(Increase)/Decrease in inventories	(14,49,94,969.44)	(8,13,72,073.17)	62,96,119.57
Increase/(Decrease) in other current liabilities	4,15,84,064.36	90,39,722.63	1,17,73,285.46
(Increase)/Decrease in short term loans and advances	(1,22,03,064.16)	(1,61,33,495.27)	(76,256.19)
(Increase)/Decrease in other current assets	(1,37,72,454.11)	(1,59,45,989.16)	(4,17,891.38)
<b>Net Changes in working capital</b>	<b>(12,17,20,655.87)</b>	<b>(19,69,35,784.84)</b>	<b>(13,25,04,270.12)</b>
<b>Net cashflow from Operating Activities (A)</b>	<b>13,11,60,790.08</b>	<b>23,38,24,928.06</b>	<b>8,79,89,298.45</b>
<b>B CASHFLOW FROM INVESTING ACTIVITIES</b>			
Purchase of tangible/intangible assets	(6,96,67,153.47)	(18,21,18,569.93)	(8,81,65,187.10)
Interest received	45,31,698.19	66,29,830.03	29,51,597.54
Cash used for Non Current Investments	77,89,905.49	-	-
Cash used for Long Term Loans/Advances	(1,61,97,373.47)	(1,52,00,609.89)	(16,13,915.50)
<b>Net cash used in Investing Activities (B)</b>	<b>(7,35,42,923.26)</b>	<b>(19,06,89,349.79)</b>	<b>(8,68,27,505.06)</b>
<b>C CASHFLOW FROM FINANCING ACTIVITIES</b>			
Finance Cost	(1,37,05,153.47)	(2,41,47,824.09)	(1,14,05,849.82)
Increase in/(Repayment) of Short term Borrowings	29,72,965.97	4,31,42,466.70	4,17,77,060.40
Increase in/(Repayment) of Long term Borrowings	(49,82,104.63)	(4,37,30,925.02)	(4,43,64,348.35)
Increase/ (Decrease) in share capital	-	-	-
Increase/ (Decrease) in share premium	-	-	-
Other Inflows/ (Outflows) of cash	-	-	-
<b>Net cash used in Financing Activities (C)</b>	<b>(1,57,14,292.13)</b>	<b>(2,47,36,282.41)</b>	<b>(1,39,93,137.77)</b>
<b>D Net Increase/(Decrease) in cash &amp; cash equivalents (A+B+C)</b>	<b>4,19,03,574.69</b>	<b>1,83,99,295.86</b>	<b>(1,28,31,344.38)</b>
<b>E Cash &amp; Cash equivalents at beginning of period</b>	<b>19,16,39,636.83</b>	<b>17,32,40,340.97</b>	<b>17,32,40,340.97</b>
<b>F Cash &amp; Cash equivalents at end of period</b>	<b>23,35,43,211.52</b>	<b>19,16,39,636.83</b>	<b>16,04,08,996.59</b>
<b>G Net Increase/(Decrease) in cash &amp; cash equivalents (F-E)</b>	<b>4,19,03,574.69</b>	<b>1,83,99,295.86</b>	<b>(1,28,31,344.38)</b>

- The above results have been reviewed by the Audit Committee and taken on record by Board of Directors at their respective meetings held at 07th November' 2023.
- The company is engaged in single business segment i.e. Pharmaceuticals.
- Figures are regrouped/rearranged, wherever considered necessary.

**For KALRA RAI AND ASSOCIATES**

Chartered Accountants

(FRN : 008859N)

FRN 008859N

**LAJPAT RAI KALRA**

**PARTNER**

Membership No. : 087438

Place : Chandigarh

Date : 07/11/2023

*[Signature]*  
13

**RAHUL BATRA**  
MANAGING DIRECTOR  
DIN : 02229234

**For and on Behalf of Board of Directors**

*[Signature]*  
**RAJNIBRAR**  
COMPANY SECRETARY  
ACS24684

*[Signature]*  
**NIPUN ARORA**  
CFO  
FCA514044





**KALRA RAI & ASSOCIATES**  
**A Peer Review Firm**  
**CHARTERED ACCOUNTANTS**

M : +91-98880-66743

Phone - 0172-4640667

E-mail : kalrarai@gmail.com  
kalrarai667@hotmail.com

Head Office : Kothi No. 667, 1st Floor, Sector-43 A, Chandigarh - 160022

**LIMITED REVIEW REPORT**

**Independent Auditor's Review report on Interim Un-Audited Standalone Financial Results for the half year ended on 30<sup>th</sup> September, 2023 pursuant to Regulation 33 of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015 (as amended)**

To,  
The Board of Directors of  
M/s Beta Drugs Limited  
Village Nandpur, Lodhimajra Road  
Baddi, Distt Solan  
H.P. 174101

We have reviewed the accompanying statement of unaudited standalone financial results of **M/s Beta drugs Limited ("the company")** for the half year ended **30<sup>th</sup> September, 2023**. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For KALRA RAI & ASSOCIATES  
Chartered Accountants

(LAJPAT RAI KALRA)

Partner

M. No.: -087438

Place: Chandigarh

Date: 07.11.2023

**Branch Office Mohali :-**

Plot No. 775, Sector-82, JLPL, Mohali, Punjab-160082

EMAIL : kalrarai@rediffmail.com

**Branch Office Delhi :-**

I-50, 4th Floor, Lagpat Nagar-1, New Delhi - 110024, Ph. : 011-43034803

EMAIL : advphagunkalra@gmail.com | Cell : +91-77989-06173



**BETA DRUGS LIMITED**  
Village Nandpur, Lodhimajra Road, Tehsil. Baddi, Distt. Solan, (H.P.) 173205  
Phone : 01795-236196 E-Mail : betabaddi@gmail.com  
CIN No. L24230HP2005PLC028969

Audited Standalone Financial Results for the year ended on 30th September' 2023

Particulars	6 Months Ended on 30/09/2023 (Unaudited)	6 Months Ended on 31/03/2023 (Audited)	6 Months Ended on 30/09/2022 (Unaudited)	Year Ended on 31/03/2023 (Audited)
I. Revenue From Operations	92,41,54,635.28	79,90,69,508.92	77,96,76,364.53	1,57,87,45,873.45
II. Other Income	65,91,034.94	56,31,067.27	47,96,680.00	1,04,27,747.27
III. Total Revenue (I+II)	93,07,45,670.22	80,47,00,576.19	78,44,73,044.53	1,58,91,73,620.72
IV. Expenses				
a) Cost of Materials Consumed	56,00,94,123.50	44,41,93,216.81	42,04,90,601.28	86,46,83,818.09
b) Purchase of Stock-in-Trade	-	-	-	-
c) (Increase)/Decrease in Stock of Finished Goods/WIP	(5,81,64,020.61)	(2,61,42,428.76)	-55,52,984.99	(3,16,95,413.75)
d) Other Manufacturing expenses	8,14,18,796.00	7,66,81,963.15	7,55,05,001.81	15,21,87,691.22
e) Employee benefit expenses	6,72,72,657.25	6,86,19,806.41	6,55,87,865.75	13,42,07,672.16
f) Finance Costs	57,31,937.94	53,81,250.82	29,84,858.46	83,66,109.28
g) Depreciation & amortisation expenses	3,03,94,899.68	3,22,72,261.88	2,96,76,096.51	6,19,48,358.39
h) Other expenses	8,18,92,753.60	8,12,64,901.99	6,61,16,641.94	14,73,80,817.67
Total Expenses	76,86,41,147.36	68,22,70,972.30	65,48,08,080.76	1,33,70,79,053.06
V. Profit before exceptional and extraordinary items and tax (III-IV)	16,21,04,522.86	12,24,29,603.89	12,96,64,963.77	25,20,94,567.66
VI. Exceptional Items	-	-	-	-
VII. Profit before extraordinary items and tax (V-VI)	16,21,04,522.86	12,24,29,603.89	12,96,64,963.77	25,20,94,567.66
VIII. Extraordinary Items				
IX. Profit before tax (VII-VIII)	16,21,04,522.86	12,24,29,603.89	12,96,64,963.77	25,20,94,567.66
X. Tax Expenses				
a) Current year tax	4,19,67,023.38	3,30,12,678.70	3,38,26,031.75	6,68,38,710.45
b) MAT credit/Deferred tax	(9,77,895.64)	(17,12,897.46)	(11,91,953.67)	(29,04,851.13)
XI. Profit (Loss) for the period from continuing operations (IX-X)	12,11,15,395.12	9,11,29,822.65	9,70,30,885.69	18,81,60,708.34
XII. Profit (Loss) from discounting operations				
XIII. Tax expenses of discounting operations				
XIV. Profit (Loss) from discounting operation (after tax) (XII-XIII)	-	-	-	-
XV. Net Profit/(Loss) for the period (XI+XIV)	12,11,15,395.12	9,11,29,822.65	9,70,30,885.69	18,81,60,708.34
XVI. Earning per share				
a) Basic	12.60	9.48	10.09	19.57
b) Diluted	12.60	9.48	10.09	19.57
XVIII. Paid up equity share capital	9,61,37,900.00	9,61,37,900.00	9,61,37,900.00	9,61,37,900.00
Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	97,97,39,177.06	86,64,13,687.44	77,55,09,345.39	86,64,13,687.44

- The above results have been reviewed by the Audit Committee and taken on record by Board of Directors at their respective meetings held at 07th November' 2023.
- The company is engaged in single business segment i.e. Pharmaceuticals.
- Figures are regrouped/rearranged, wherever considered necessary.

For KALRA RAI AND ASSOCIATES  
Chartered Accountants  
(FRN : 008859N)

Accountants  
FRN 008859N


LAJPAT RAI KALRA  
PARTNER

Membership No. : 087438


UDIN: 23087438BGVHLS6064

Place : Chandigarh

Date : 07/11/2023

  
RAHUL BATRA  
MANAGING DIRECTOR  
DIN : 02229234

  
RAJNI BRAR  
COMPANY SECRETARY  
ACS24684

For and on Behalf of Board of Directors  
  
NIPUN ARORA  
CFO  
FCA514044



# BETA DRUGS LIMITED

Village Nandpur, Lodhimajra Road, Tehsil. Baddi, Distt. Solan, (H.P.) 173205

Phone : 01795-236196 E-Mail : betabaddi@gmail.com

CIN No. L24230HP2005PLC028969

Standalone Statement of Assets & Liabilities for the year ended on 30th September' 2023

Particulars	As at 30th September' 2023	As at 31st March' 2023	As at 30th Sep' 2022
	Amount in Rs.	Amount in Rs.	Amount in Rs.
<b>1. EQUITY AND LIABILITIES</b>			
<b>(A) Shareholder's Funds</b>			
(a) Share Capital	9,61,37,900.00	9,61,37,900.00	9,61,37,900.00
(b) Reserves and Surplus	97,97,39,177.06	86,64,13,687.44	77,55,09,345.39
(c) Money received against share warrants			
<b>Sub-total-Shareholders' funds</b>	<b>1,07,58,77,077.06</b>	<b>96,25,51,587.44</b>	<b>87,16,47,245.39</b>
<b>(B) Non- Current Liabilities</b>			
(a) Long-term borrowings	2,95,14,564.74	3,72,87,825.36	4,21,47,956.00
(b) Deferred tax liabilities (Net)	-	-	-
(c) Other Long term liabilities	1,62,89,288.01	1,50,49,969.37	1,76,14,737.82
(d) Long term Provisions	1,08,12,022.00	1,08,12,022.00	95,57,629.00
<b>Sub-total-Non- current liabilities</b>	<b>5,66,15,874.75</b>	<b>6,31,49,816.73</b>	<b>6,93,20,322.82</b>
<b>(C) Current Liabilities</b>			
(a) Short-term borrowings	-	-	-
(b) Trade Payable	30,37,11,269.34	23,21,25,393.90	20,74,71,345.33
(c) Other current liabilities	8,59,46,975.38	5,31,94,311.53	5,50,40,914.16
(d) Short-term provisions	2,89,25,663.43	2,94,28,046.01	2,68,00,883.16
<b>Sub-total-current liabilities</b>	<b>41,85,83,908.15</b>	<b>31,47,47,751.44</b>	<b>28,93,13,142.65</b>
<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>1,55,10,76,859.97</b>	<b>1,34,04,49,155.61</b>	<b>1,23,02,80,710.86</b>
<b>2. ASSETS</b>			
<b>(A) Non-current assets</b>			
(a) Property, Plant & Equipment and Intangible Assets			
(i) Property, Plant & Equipment	33,72,40,932.37	33,24,86,643.97	34,13,94,284.36
(ii) Intangible assets	2,04,02,036.24	1,52,31,151.40	1,12,81,137.74
(iii) Capital work-in-progress	-	-	-
(b) Non Current Investments	5,77,40,000.00	6,55,29,905.49	6,54,29,905.49
(c) Long Term Loan & Advance	8,37,07,092.86	6,77,71,564.40	6,11,82,823.76
(d) Other Non Current Assets	5,00,000.00	5,00,000.00	5,00,000.00
(e) Deferred tax Assets	99,01,241.38	89,23,345.75	72,10,448.28
<b>Sub-total-Non-current assets</b>	<b>50,94,91,302.86</b>	<b>49,04,42,611.01</b>	<b>48,69,98,599.63</b>
<b>(B) Current Assets</b>			
(a) Inventories	20,50,08,334.09	13,66,35,012.49	9,52,81,434.16
(b) Trade receivable	49,98,05,258.79	43,59,47,822.68	42,04,44,711.22
(c) Cash and bank balance	21,78,88,061.54	17,79,40,847.11	14,51,60,196.96
(d) Short-term loan and advances	3,96,31,765.21	2,85,00,578.37	2,47,18,224.45
(e) Other current assets	7,92,52,137.48	7,09,82,283.95	5,76,77,544.44
<b>Sub-total-current assets</b>	<b>1,04,15,85,557.11</b>	<b>85,00,06,544.60</b>	<b>74,32,82,111.23</b>
<b>TOTAL - ASSETS</b>	<b>1,55,10,76,859.97</b>	<b>1,34,04,49,155.61</b>	<b>1,23,02,80,710.86</b>

- The above results have been reviewed by the Audit Committee and taken on record by Board of Directors at their respective meetings held at 07th November' 2023.
- The company is engaged in single business segment i.e. Pharmaceuticals.
- Figures are regrouped/rearranged, wherever considered necessary.

For KALRA RAI AND ASSOCIATES

Chartered Accountants

(FRN : 008859N)

LAJPAT RAI KALRA

PARTNER

Membership No. : 087438

UDIN: 23087438B6VHLS6064

Place : Chandigarh

Date : 07/11/2023



RAHUL BATRA  
MANAGING DIRECTOR  
DIN : 02229234

RAJNI BRAR  
COMPANY SECRETARY  
ACS24684

NIPUN ARORA  
CFO  
FCA514044

For and on Behalf of Board of Directors



BETA DRUGS LIMITED				
Village Nandpur, Lodhimajra Road, Tehsil. Baddi, Distt. Solan, (H.P.) 173205				
Phone : 01795-236196 E-Mail : betabaddi@gmail.com				
CIN No. L24230HP2005PLC028969				
Standalone Cashflow Statement for the year ended on 30th September' 2023				
Particulars		As at 30 September'	As at 31 March' 2023	As at 30 September'
		2023		2022
		Amount in Rs.	Amount in Rs.	Amount in Rs.
A	CASHFLOW FROM OPERATING ACTIVITIES			
	Net Profit before tax and extraordinary items (as per Statement of Profit & Loss)	16,21,04,522.86	25,20,94,567.66	12,96,64,963.77
	Adjustments for non Cash/Non trade items:			
	Depreciation & Amortization Expenses	3,03,94,899.68	6,19,48,358.39	2,96,76,096.51
	Finance Cost	57,31,937.94	83,66,109.28	29,84,858.46
	Interest received	(64,98,305.94)	(98,83,836.00)	(46,27,397.00)
	Other inflows/(outflows) of cash	(5,02,59,311.44)	(5,61,84,164.19)	(2,68,27,560.74)
	Operating profits before Working Capital Changes	14,14,73,743.10	25,63,41,035.14	13,08,70,961.00
	Adjusted For:			
	(Increase)/Decrease in trade receivables	(6,38,57,436.11)	(12,24,05,527.43)	(10,69,02,415.97)
	Increase/(Decrease) in trade payables	7,15,85,875.44	3,54,96,615.56	1,08,42,566.99
	(Increase)/Decrease in inventories	(6,83,73,321.60)	(5,19,33,356.38)	(1,05,79,778.05)
	Increase/(Decrease) in other current liabilities	3,27,52,663.85	1,07,30,936.58	1,25,77,539.21
	(Increase)/Decrease in short term loans and advances	(1,11,31,186.84)	(94,75,384.39)	(56,93,030.47)
	(Increase)/Decrease in other current assets	(82,69,853.53)	(1,64,90,779.95)	(31,86,040.44)
	Net Changes in working capital	(4,72,93,258.79)	(15,40,77,496.01)	(10,29,41,158.73)
	Net cashflow from Operating Activities (A)	9,41,80,484.31	10,22,63,539.13	2,79,29,802.27
B	CASHFLOW FROM INVESTING ACTIVITIES			
	Purchase of tangible/intangible assets	(4,03,20,072.93)	(6,90,95,070.58)	(4,17,80,435.42)
	Interest received	64,98,305.94	98,83,836.00	46,27,397.00
	Cash used for Non Current Investments	77,89,905.49	(1,00,000.00)	-
	Cash used for Long Term Loans/Advances	(1,59,35,528.46)	11,12,697.46	77,01,438.10
	Net cash used in Investing Activities (B)	(4,19,67,389.96)	(5,81,98,537.12)	(2,94,51,600.32)
C	CASHFLOW FROM FINANCING ACTIVITIES			
	Finance Cost	(57,31,937.94)	(83,66,109.28)	(29,84,858.46)
	Increase in/(Repayment) of Short term Borrowings	-	-	-
	Increase in/(Repayment) of Long term Borrowings	(65,33,941.98)	(1,35,64,699.63)	(61,39,800.54)
	Increase/ (Decrease) in share capital	-	-	-
	Increase/ (Decrease) in share premium	-	-	-
	Other Inflows/ (Outflows) of cash	-	-	-
	Net cash used in Financing Activities (C)	(1,22,65,879.92)	(2,19,30,808.91)	(91,24,659.00)
D	Net Increase/(Decrease) in cash & cash equivalents (A+B+C)	3,99,47,214.43	2,21,34,193.10	(1,06,46,457.05)
E	Cash & Cash equivalents at beginning of period	17,79,40,847.11	15,58,06,654.01	15,58,06,654.01
F	Cash & Cash equivalents at end of period	21,78,88,061.54	17,79,40,847.11	14,51,60,196.96
G	Net Increase/(Decrease) in cash & cash equivalents (F-E)	3,99,47,214.43	2,21,34,193.10	(1,06,46,457.05)
1 The above results have been reviewed by the Audit Committee and taken on record by Board of Directors at their respective meetings held at 07th November' 2023.				
2 The company is engaged in single business segment i.e. Pharmaceuticals.				
3 Figures are regrouped/rearranged, wherever considered necessary.				
For KALRA RAI AND ASSOCIATES Chartered Accountants (FRN : 008859N)		For and on Behalf of Board of Directors		
				
LALPAT RAI KALRA PARTNER Membership No. : 087438 Place : Chandigarh Date : 07/11/2023		RAHUL BATRA MANAGING DIRECTOR DIN : 02229234		
		RAJNI BRAR COMPANY SECRETARY ACS24684		
		NIPUN ARORA CFO FCA514044		





# BETA DRUGS LIMITED

**BDL/PKL/SEC/2023**  
**7<sup>th</sup> November, 2023**

To  
The Listing Department  
National Stock Exchange of India Ltd.  
Exchange Plaza, 5th Floor  
Plot no. C/I, G Block  
Bandra-Kurla Complex, Bandra (E)  
Mumbai — 400 051.

**Sub: Certificate as per regulation 33(2)(a) of SEBI(LODR) Regulations, 2015**

Dear Sir/Madam

We the undersigned, in our respective capacities as Managing Director and Chief Financial Officer of Beta Drugs Limited, certify that the Un-Audited Standalone and Consolidated Financial results for the half year ended 30<sup>th</sup> September, 2023, do not contain any false or misleading statement or figures and do not omit any material fact which may make the statements or figures contained therein misleading.

Thanking You  
Your's faithfully

**For Beta Drugs Limited**

  
**Mr Rahul Batra**  
**Managing Director**  
**DIN: 02229234**

  
**Mr Nipun Arora,**  
**Chief Financial Officer**

**CIN No.: L24230HP2005PLC028969**

**Admin. Office :** SCO 184, Sector-5, Panchkula-134 114 Haryana (INDIA) Phone: +91-172-2585481-482-483

**Registered Office & Works:** Vill. Nandpur, Lodhimajra Road, Tehsil. : Baddi, Distt. Solan, H.P. Phone No. : 01795-236196

**Website :-** [www.betadrugslimited.com](http://www.betadrugslimited.com)

**E-Mail :-** [info@betadrugslimited.com](mailto:info@betadrugslimited.com)